---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-090834"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2025-09-17T23:59:59+00:00"
generated_at: "2026-05-17T06:21:13.725755+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports FY2025 net loss $74.4M; sunRIZE topline Dec 2025, FDA streamlines tumor HI trial

## Summary
- Net loss of $24.4M for Q4 FY2025, $74.4M full year; cash $167.9M as of June 30, 2025 (up from $127.1M).
- Phase 3 sunRIZE (congenital HI) fully enrolled with 62 participants; topline results expected December 2025.
- FDA aligned on streamlined Phase 3 upLIFT (tumor HI) with as few as 16 participants; topline H2 2026.
- Appointed Dr. Sunil Karnawat as Chief Commercial Officer in August 2025 to lead launch strategy.
- R&D expenses $61.5M (FY2025) vs $55.7M; G&A $18.4M vs $14.7M; increases driven by trial and headcount.

## SEC filing metadata
- accession: 0001104659-25-090834
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2025-09-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/0001104659-25-090834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/tm2526049d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-090834
- JSON: https://secwatch.observer/filing/0001104659-25-090834.json
- Plain text: https://secwatch.observer/filing/0001104659-25-090834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.